CELC
Celcuity Inc.
NASDAQ · Healthcare · Biotechnology · US
$94.77
−1.73%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -36.7%
- EBIT
- -42.3%
- EPS
- -24.3%
- Free cash flow
- -59.3%
- Operating cash flow
- -59.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -9.3%
- EPS
- +3.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- -57.6%
- EBIT
- -52.0%
- Net income
- -58.4%
- EPS
- -33.6%
- Free cash flow
- -83.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026